Efficacy of Focal Adhesion Kinase Inhibition in Meningiomas With Somatic NF2 Mutations
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Disclosure statements are available on the authors' profiles:
Alliance A071401: Phase II Trial of Focal Adhesion Kinase Inhibition in Meningiomas With Somatic NF2 Mutations
J. Clin. Oncol 2022 Oct 26;[EPub Ahead of Print], PK Brastianos, EL Twohy, ER Gerstner, TJ Kaufmann, AJ Iafrate, J Lennerz, S Jeyapalan, DE Piccioni, V Monga, CE Fadul, D Schiff, JW Taylor, SA Chowdhary, C Bettegowda, G Ansstas, M De La Fuente, MD Anderson, N Shonka, D Damek, J Carrillo, LJ Kunschner-Ronan, R Chaudhary, KA Jaeckle, FM Senecal, T Kaley, T Morrison, AA Thomas, MR Welch, F Iwamoto, D Cachia, AL Cohen, S Vora, M Knopp, IF Dunn, P Kumthekar, J Sarkaria, S Geyer, XW Carrero, M Martinez-Lage, DP Cahill, PD Brown, C Giannini, S Santagata, FG Barker, E GalanisFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Brain Cancer Center of Excellence
Visit our Brain Cancer Center of Excellence for additional, in-depth coverage.